XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc. (XYN) is a clinical-stage biopharmaceutical company that entered the public markets through a business combination with Panacea Acquisition Corp., a healthcare-focused special purpose acquisition company sponsored by Panacea Capital Group LLC that completed its IPO in 2018. The company's November 2019 Form 10-Q quarterly filing reflects operations under the combined public entity following the closing of that SPAC merger. Xynomic concentrates its pipeline on oncology therapeutics, positioning it within the pharmaceutical and life sciences sector. The combined company trades under the XYN ticker. For full filing history, deal timelines, and analytics on XYN and hundreds of other SPAC transactions, sign up for complete data access at SpacDesk.